New drugs: Nebivolol (Aust Prescr 2010;33:55–6)
Following receipt of correspondence, which is published on pages 101–2 in this issue, the New drug comment on nebivolol has been corrected as follows. In paragraph 6 the third sentence has been deleted ('This was apost hoc analysis … different doses of nebivolol.')
Also in paragraph 6, the fifth sentence ('The target dose … compared to placebo.') has been corrected to 'The target dose was reached by two-thirds of the patients in the nebivolol group. Nebivolol was associated with a significant reduction (absolute risk reduction of 4.2%) in the composite end point of all-cause mortality or hospitalisation (due to a cardiovascular event), compared to placebo.'
Reference 5 has been replaced by
5. Flather MD, Shibata MC, Coats AJ, Van Veldhuisen DJ, Parkhomenko A, Borbola J, et al.; SENIORS Investigators. Randomized trial to determine the effect of nebivolol on mortality and cardiovascular hospital admission in elderly patients with heart failure (SENIORS). Eur Heart J 2005;26:215-25.
New drugs: Miglustat (Aust Prescr 2010;33:92–3)
Paragraph 4 should start 'Regular intravenous infusion of recombinant glucocerebrosidase ...'.
Self-test questions (Aust Prescr 2010;33:84-7)
Questions 1 and 2 on page 87 should be 3 and 4.
